December 8, 2020 11:06 AM | With information from EFE
15 minutes. The Food and Drug Administration (FDA) of the United States (USA) confirmed this Tuesday the safety and efficacy of the COVID-19 vaccine from Pfizer and BioNTech in a first analysis prior to authorization. In this way, he pointed out that vaccination could begin in the country in the coming days.
In its analysis, the FDA noted that the vaccine, the first considered for distribution in the US, met “the prescribed success criteria” in a clinical study.
The report states that the vaccine, which requires 2 doses, guarantees “the reduction of the risk of COVID-19 confirmed at least 7 days after dose 2.” Likewise, “a reduction in the risk of confirmed severe COVID-19 at any time after dose 1 “.
The index of efficacy is 95% in general and 94% among those over 65 years of age (population at risk). Therefore, it is much higher than the 50% required by the FDA to approve COVID-19 vaccine candidates.
This Thursday, an independent scientific body will review these results. If agreed with the FDA, it would open the possibility of beginning distribution this weekend.
The calculations of the US authorities suggest that 20 million people in the country could be vaccinated before the end of the year.
The United Kingdom began this Tuesday to supply the first doses of the vaccine from Pfizer and BioNTech for the immunization of the population.
The United States is the country hardest hit by the pandemic in the world, with more than 15 million infected and 280,000 dead, according to the independent count from Johns Hopkins University.